HEPHAISTOS Pharma is developing a TLR4 agonist meant to overcome immunosuppressive tumor environments. It has benefited from Paris Saclay Cancer Cluster's BOOST activator program
- Jun 4
- 1 min read
CEO Frédéric Caroff describes the program, and how it is meant to activate both the innate and adaptive immune systems, and how the support of BOOST has helped the company.










.png)